Hutchison China MediTech Limited (HCM) News

Hutchison China MediTech Limited (HCM): $9.23

0.17 (+1.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HCM to Watchlist
Sign Up

Industry: China


Ranked

of 43

in industry

Filter HCM News Items

HCM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HCM News Highlights

  • For HCM, its 30 day story count is now at 3.
  • Over the past 6 days, the trend for HCM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about HCM are AIM, GTH and PD.

Latest HCM News From Around the Web

Below are the latest news stories about HUTCHMED (China) Ltd that investors may wish to consider to help them evaluate HCM as an investment opportunity.

Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLC

BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for

Yahoo | February 10, 2022

HUTCHMED to Announce 2021 Final Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00 am Eastern Standard Time (EST) / 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

Yahoo | February 7, 2022

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel selective inhibitor targeting fibroblast growth factor receptors (“FGFR”) 1/2/3, in combination with chemotherapy or the anti-PD-1 therapy, toripalimab. The first patient received their first dose on January 22, 2022. The clinical trial is a m

Yahoo | February 4, 2022

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor (“CSF-1R”) inhibitor. The first patient received their first dose on January 18, 2022. The Phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability,

Yahoo | January 20, 2022

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US. Further details of the presenta

Yahoo | January 19, 2022

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (“ITP”) patients who have received at le

Yahoo | January 12, 2022

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 that also target the B-cell receptor (“BCR”) signaling pathway, and tazemetostat and HMPL-306 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) has initiated a Phase

Yahoo | January 10, 2022

HUTCHMED Included in FTSE Russell Indexes

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”) in its quarterly review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on Monday, December 20, 2021. FTSE Russell is a global index leader that provid

Yahoo | December 20, 2021

Virtus AllianzGI International Small-Cap Fund Buys Alchip Technologies, Sojitz Corp, Bystronic ...

Investment company Virtus AllianzGI International Small-Cap Fund (Current Portfolio) buys Alchip Technologies, Sojitz Corp, Bystronic AG, Industrial & Infrastructure Fund Investment Corp, JMDC Inc, sells Marui Group Co, HELLA GmbH KGaA, OC Oerlikon Corp AG, Pfaffikon, Showa Denko KK, Open House Co during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Virtus AllianzGI International Small-Cap Fund.

Yahoo | December 11, 2021

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 10, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalimab, in multiple disease settings, presented at the European Society for Medical Oncology’s (ESMO) Immuno-Oncology Congress 2021, taking place virtually on December 8-11, 2021. Further details of the poster presentations are as follows: Title:Surufa

Yahoo | December 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7587 seconds.